News

A Landscape of Pharmacogenomic Interactions in Cancer

The journal Cell published a study today (July 7) about the integrated analysis of drug response in 1,001 cancer cell lines. This study was undertaken by a large international group of researchers including ISB Senior Research Scientist Theo Knijnenburg. The researchers integrated heterogeneous molecular data of 11,215 tumors and 1,001 cell lines in order to study the drug response of these cell lines to 265 anti-cancer drugs. They uncovered numerous oncogenic aberrations that sensitize to an anti-cancer drug. This study is expected to form an important resource to identify therapeutic options for cancer sub-populations.
Read More

Recent Articles

  • Spotlight on Caroline Cannistra, ISB Systems Research Scholar

    Caroline Cannistra joined ISB in 2018 as a Systems Research Scholar. The Systems Research Scholars Program provides recent college undergraduates a springboard to become the next generation’s pioneers of interdisciplinary scientific research.

  • 2019 education awards

    ISB’s Mónica Orellana, Nyasha Chambwe Honored With Inaugural Education Recognition Awards

    At ISB, many of our scientists and STEM professionals give their time and expertise and make profound impacts on our educational programs. Two of our researchers — Dr. Mónica Orellana and Dr. Nyasha Chambwe — were honored with inaugural Education Recognition Awards for their devotion to providing quality STEM education.

  • TCGA, ISB Researchers Identify Potential Drug Targets for Leading Form of Deadly Liver Cancer

    June 19, 2017 Researchers in ISB’s Shmulevich Lab and their colleagues in The Cancer Genome Atlas Research Network performed the first large-scale, multi-platform analysis of hepatocellular carcinoma, the predominant form of liver cancer. Study was published on June 15, 2017, in the journal Cell. 3 Bullets: Liver cancer is the second most common cause of death from cancer worldwide. ISB researchers and colleagues from The Cancer Genome Atlas Research Network…